Healthpeak Properties, Inc. is a real estate investment trust that owns, operates, and develops healthcare-focused real estate in the United States. Founded in 1985, the company manages a portfolio across three core asset classes: outpatient medical, laboratory, and senior housing. The outpatient medical segment includes medical office buildings and hospitals, while the laboratory segment comprises research facilities for life sciences. The senior housing segment consists of life plan communities and senior housing facilities, which are operated through RIDEA structures and are slated for contribution to a newly formed entity, Janus Living, Inc. Healthpeak serves tenants including pharmaceutical, biotechnology, and medical device companies, as well as healthcare delivery systems and specialty physician groups. Notable properties in its portfolio include Torrey Pines Science Park, The Cove at Oyster Point, and Medical City Dallas. The company completed a merger with Physicians Realty Trust in March 2024, acquiring additional outpatient medical buildings. Healthpeak operates through its consolidated subsidiary Healthpeak OP and maintains an investment-grade balance sheet with long-term fixed-rate debt financing.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry REIT - Specialty Homepage healthpeak.com
Sector Real Estate IR page ir.healthpeak.com/overview/default.aspx
Tags
healthcare real estate, outpatient medical, laboratory, senior housing, life plan communities, medical office buildings, research facilities, property management, real estate development, Healthpeak OP, Janus Living Inc., Physicians Realty Trust, Torrey Pines Science Park, The Cove at Oyster Point, Medical City Dallas, Cambridge Discovery Park, Baylor Scott & White Charles A. Sammons Cancer Center, Gateway Crossing
Press page —

Metrics

Valuation  
Market cap $ 14.329B
Market cap (USD) $ 14.329B
P/E 38.47
PEG —
P/BV 1.82
P/S 17.04
P/OCF 11.28
P/FCF 40.13
Dividend yield 5.9%
Turnover / mcap —
Returns  
ROE 0.90%
ROI 0.39%
ROIC 2.9%
Profit margin 11.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -47.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 119.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 39
Quality score 26.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 603.989M 568.475M 527.417M 494.935M 471.325M 436.494M 727.98M 1.847B 1.848B 2.129B 2.544B 2.266B 2.1B 1.901B 1.725B 1.255B 1.157B 1.026B 982.509M 619.087M 477.276M 428.684M 400.183M 359.576M 332.46M 329.807M
Net profit 71.347M 243.142M 306.009M 500.449M 505.54M 413.563M 45.53M 1.061B 414.169M 627.747M -559.235M 922.233M 970.837M 832.54M 538.891M 330.709M 146.151M 448.495M 589.015M 417.547M 173.057M 169.04M 158.585M 137.38M 121.166M 133.767M
Free cash flow 357.01M 333.734M 181.681M -61.733M 35.528M -30.464M 102.115M 241.523M 375.263M 755.231M 833.994M — — — — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 16.08 20.27 19.8 25.07 36.09 30.23 34.47 27.92 26.08 29.72 14.71 15.88 11.5 — — — — — — — — — — — — —
Price performance 12m -0.21 0.02 -0.21 -0.31 0.19 -0.12 0.23 0.07 -0.12 1.02 -0.07 0.38 — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 0.00 157M 180M 205M 209M 207M 307M 296M
Cash and deposits (USD) 94.7M 55.3M 111M 144M 44.2M 158M 72M 118M 120M 467M
Intangible assets (USD) 480M 410M 305M 332M 520M 520M 418M 314M 817M 655M
Right-of-use assets (USD) — — 0.00 172M 192M 234M 237M 240M 424M 412M
Cash flow detail
Operating cash flow (USD) 1.21B 847M 849M 846M 758M 795M 900M 956M 1.07B 1.25B
Purchases of property, plant and equipment (USD) -459M -472M -607M -744M -789M -760M -962M -775M -737M -895M
Change in receivables (cash effect) (USD) 3.81M — — — — — — — — —
Change in payables (cash effect) (USD) 42M 4.82M 40.6M 71.7M 93.5M 7.77M 136M 105M 85.6M -25.3M
Dividends paid (cash effect) (USD) -980M -695M -697M -720M -787M -650M -648M -657M -795M -849M
Share buybacks (cash effect) (USD) -8.69M -4.79M -3.43M -5.04M -10.5M -12.8M -67.8M -6.52M -191M -97.1M
Interest paid (cash effect) (USD) -489M -309M -276M -202M -210M -173M -162M -188M -249M -260M
Income taxes paid (cash effect) (USD) -13.7M -10M -4.48M -1.43M 786,000 -4.52M 1.9M -1.92M -7.86M -3.41M
Share-based compensation (USD) 22.9M 14.3M 16.6M 18.2M 17.4M 18.2M 26.5M 14.5M 15.5M 14.4M
Operating cash flow before change in receivables (USD) 1.21B — — — — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) 755M 375M 242M 102M -30.5M 35.5M -61.7M 182M 334M 357M
Income detail
Total comprehensive income (USD) 641M 428M 1.09B 61.9M 427M 526M 548M 326M 277M 62.3M
Comprehensive income to owners (USD) 629M 420M 1.08B 47.4M 413M 506M 532M 297M 253M 32.6M
Provision for credit losses (USD) 2.31M 123,000 304,000 2.21M 513,000 -90,000 180,000 1.27M — —
Reported Feb 24, 2017 Mar 1, 2018 May 2, 2019 Feb 27, 2020 Feb 26, 2021 Feb 24, 2022 Feb 24, 2023 Feb 22, 2024 Feb 4, 2025 Feb 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Download PDF Bull 0 Bear 0 Routine

HQ Point San Diego, CA

Transaction Update November 2026

Disclaimers

Statements contained in this presentation that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, other transactions discussed in this presentation, expected initial cash yield and stabilized cash yield, the payment of dividends, and FFO as Adjusted guidance. Acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this presentation, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. As more fully set forth under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC, these risks and uncertainties include, but are not limited to: changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political administration; macroeconomic trends that may increase borrowing, construction, labor and other operating costs; changes within the life science industry, and significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; operational risks associated with our senior housing properties managed by third parties, including our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”); the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; the requirements of, or changes to, governmental

reimbursement programs such as Medicare or Medicaid; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses; our use of joint ventures may limit our returns on and our flexibility with jointly owned investments; our use of rent escalators or contingent rent provisions in our leases; competition for suitable healthcare properties to grow our investment portfolio; our ability to exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate and/or operate acquisitions or internalize property management; the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; environmental, social and governance and sustainability commitments and changing requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, and health and safety measures intended to reduce their spread; our past participation in the Coronavirus Aid, Relief, and Economic Security Act Provider Relief Fund and other Covid-related stimulus and relief programs; laws or regulations prohibiting eviction of our tenants; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology; the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors; volatility, disruption, or uncertainty in the financial markets; increased interest rates and borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all; an increase in our level of indebtedness; covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants; volatility in the market price and trading volume of our common stock; adverse changes in our credit ratings; the initial public offering of Janus Living may not achieve the intended benefits; our economic exposure to shifts in the price of Janus Living common stock and our ability to control the assets and activities of Janus Living; potential conflicts of interest in our relationship with Janus Living; our ability to maintain our qualification as a real estate investment trust (“REIT”); our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactions”; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels; ownership limits in our charter that restrict ownership in our stock, and provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC (“Healthpeak OP”) common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our SEC filings.

our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forwardlooking statements were made. Non-GAAP Financial Measures This presentation contains certain supplemental non-GAAP financial measures with respect to the Company and with respect to Janus Living, Inc. (NYSE: JAN) (“Janus Living”). While the Company believes that non-GAAP financial measures are helpful in evaluating its operating performance, the use of non-GAAP financial measures in this presentation should not be considered in isolation from, or as an alternative for, a measure of financial or operating performance as defined by GAAP. We caution you that there are inherent limitations associated with the use of each of these supplemental non-GAAP financial measures as an analytical tool. Additionally, the Company’s computation of non-GAAP financial measures may not be comparable to those reported by other REITs. See "September 30, 2026 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures of the Company, calculated and presented in accordance with GAAP, available in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results (the “Q326 Non-GAAP “). See "September 30, 2026 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures of Janus Living, calculated and presented in accordance with GAAP, available in the Investor Relations section of the Janus Living website at https://ir.janusreit.com/financials/quarterly-results.

Moreover, other risks and uncertainties of which we are not currently aware may also affect

Investor Presentation – November 2026

2

Healthpeak Platform Delivering Results Increased Guidance

▪ Increased FFO as Adjusted(1) guidance for the third time this year driven by operating performance and the benefit of external growth at Janus Living

Outpatient Medical (~50% of NOI(2)) ▪ Total occupancy, tenant retention, and new leasing commencements all accelerating; results benefitting from best-in-class platform and favorable supply-and-demand fundamentals driven by an aging population, consumer, payer, and provider preference for lower-cost outpatient settings ▪ Executed 3.2M SF of leasing YTD; TTM renewals achieved +5% cash releasing spreads with leasing costs of just 8% of ABR, and 82% retention

Strong Segment Performance

Lab (~35% of NOI) ▪ Total occupancy increased +270 bps since year-end 2025, including a +130 bps sequential increase in Q3 ▪ Lease executions totaled 480K SF during Q3, bringing YTD executions to 1M SF; leasing pipeline exceeds 2M SF Senior Housing (~15% of NOI) ▪ Janus Living achieved Q3 same-store NOI growth of +26%, driven by occupancy gains and rate growth, with favorable supply and demand supporting further occupancy and margin upside over time ▪ Record third quarter non-refundable entrance fee sales

Fortress Balance Sheet

Accretive Capital Allocation

▪ 4.7x net debt to EBITDAre(3) ▪ $3.8B of available liquidity including cash, available credit facility capacity, and undrawn term loans

▪ Capital Recycled: $1.9B of lower growth assets at a blended 6% cash yield(4)

▪ Capital Invested: $1.7B into higher return acquisitions and buybacks at a blended 6% initial cash yield and 9-10% stabilized cash yield(4) 1) 2) 3) 4)

Reconciliations of the non-GAAP financial measures can be found in the Q326 Non-GAAP. Percentages based on pro rata NOI. NOI represents Adjusted NOI which is Cash Real Estate Revenues less Cash Operating Expenses. Adjusted NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI eliminates the effects of operator transition costs and actuarial reserves for insurance claims that have been incurred but not reported. Refer to the Q326 Non-GAAP. Investor Presentation – November 2026 Net Debt to Adjusted EBITDAre as of 9/30/2026. See Q326 Non-GAAP. Disposition yields based on trailing-twelve-month cash NOI divided by sales price. Initial cash yield calculated as expected forward twelve-month cash NOI divided by purchase price. Stabilized cash yield is calculated as expected cash NOI for the twelve months after stabilization, divided by purchase price plus anticipated capex. $1.9B of capital recycling includes ~$1.7B closed YTD 2026 and an additional ~$200M expected to close in Q426.

3

2026 Capital Allocation Summary Recycled $1.9 billion of lower growth assets at a blended 6% cash yield into $1.7 billion of opportunistic higher return acquisitions and stock buybacks at a blended 6% initial cash yield and 9-10% stabilized cash yield

Recaps, Dispositions, and Loan Repayments

Acquisitions and Buybacks

■ Outpatient Recaps: Generated $1.2B in proceeds □ Blue-Chip LPs: Blackstone and Brookfield □ Healthpeak retained property management and tenant relationships □ Blended trailing cash cap rate of ~5.9%

■ Opportunistic Lab: closed $705M YTD with an additional $128M under contract(1) □ Investment basis is 50% or more below replacement cost □ In-place yield of ~6% with an expected stabilized yield of 9-10%

■ Outpatient Dispositions: $91M closed with additional ~$200M expected by year-end □ Blended trailing cash cap rate of ~7%

■ Outpatient: $38M acquisition at a 7.4% cash cap rate and a $20M, 84% preleased development start

■ Outpatient Loan Repayments: $400M in June at a 6.0% cash / 7.7% GAAP interest rate

■ Senior Housing: $714M of pre-IPO acquisitions at a blended ~6% initial yield and 8-9% expected stabilized yield ■ Buybacks: $100M in April 2026 at an average price of $16.81/sh (10+% FFO yield) HQ Point San Diego, CA

Investor Presentation – November 2026 1)

Year-to-date total includes the $600M Gateway Crossing acquisitions that closed in stages on 12/31/25 and 1/1/26.

4

Recent Lab Acquisitions

Recent and Under Contract Opportunistic Lab Acquisitions Each acquisition is part of, or an extension of, an existing Healthpeak campus where our local scale and relationships will drive near-term leasing

41%

70%

~5%

9-10%

In-place occupancy

Leasing activity on 70% of the acquired vacancy

In-place yield

Expected stabilized yield(1)

CLOSED 9/30/26

UNDER CONTRACT

UNDER CONTRACT

HQ Point

5000 Shoreline

100 Acorn Park Drive

Sorrento Mesa (San Diego)

South San Francisco

Cambridge

Price

$105M

Price

$92M

Price

$36M 129K(2)

Square feet

236K

Square feet

145K

Square feet

In-place occupancy

29%

In-place occupancy

49%

In-place occupancy

Investor Presentation – November 2026 Expected stabilized yield range is based on total estimated investment, consisting of the initial basis plus anticipated tenant improvements and leasing costs required to achieve stabilization. Square footage presented at 100%; approximately 66,000 square feet is attributable to the 51% interest being acquired. Following the acquisition, Healthpeak will fully-own 100 Acorn Park Drive.

53% 6

Healthpeak Sorrento Mesa Portfolio HQ Point is a newly-constructed campus that sits within Healthpeak’s existing footprint in West Sorrento Mesa with great visibility and accessibility off Interstate 805

N W

HQ Point

Sorrento Summit

E S

236K SF

125K SF

Sorrento Highlands 130K SF

Vista Sorrento 145K SF

Gateway at Directors 165K SF

Directors Place Campus 200K SF

Legend Healthpeak Owned Recent Acquisition

05 Investor Presentation – November 2026

7

Healthpeak South San Francisco Portfolio 5000 Shoreline is a lab building that sits adjacent to and in between millions of square feet of Healthpeak real estate in South San Francisco

Point Grand and Vantage(1) 1.5M SF | 59 acres

Gateway 1.6M SF | 43 acres

Edgewater

Sierra Point(2)

170K SF | 8 acres

Cove and Portside 2.0M SF | 53 acres

1.2M SF | 46 acres

5000 Shoreline 145K SF (pending)

W

Legend

N

S

Healthpeak Owned

E

Pending Acquisition

Inclusive of Point Grand, Vantage, Nexus on Grand, and Modular Labs. Inclusive of The Shore, The Towers, and Shoreline Court.

Investor Presentation – November 2026

8

Healthpeak Cambridge Portfolio 100 Acorn Park Drive represents the buyout of a JV partner, allowing Healthpeak to fully own and control its entire footprint in Cambridge

Cambridge Point Master Plan

S

W

E

N

40 acres

Cambridgepark Drive 450K SF

Cambridge Discovery Park Campus MBTA Station

605K Total SF

100 Acorn Park Drive 129K SF (pending)

Legend Healthpeak Owned Pending Acquisition Investor Presentation – November 2026

9

November 02, 2026

DENVER--(BUSINESS WIRE)-- Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended September 30, 2026.

THIRD QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS

  • Net income of $0.02 per share and FFO as Adjusted of $0.44 per share
  • Outpatient Medical new and renewal lease executions totaled 846,000 square feet, bringing year-to-date Outpatient Medical lease executions to 3.2 million square feet
    • Subsequent to the third quarter, 1.3 million square feet of Outpatient Medical leases have been executed or are under letter of intent ("LOI")
  • Lab new and renewal lease executions totaled 480,000 square feet, bringing year-to-date Lab lease executions to 1 million square feet
    • Subsequent to the third quarter, 643,000 square feet of Lab leases have been executed or are under LOI
    • Lab total occupancy increased sequentially by +130 basis points ("bps") and is up +270 bps since year-end 2025
  • Janus Living (NYSE: JAN) reported year-over-year revenue and Adjusted EBITDAre growth of 78% and 101%, respectively
  • Acquired, or under contract to acquire, four life science buildings totaling approximately 510,000 square feet across three campuses for approximately $233 million
  • Entered into a new $500 million unsecured delayed-draw term loan facility
  • Net Debt to Adjusted EBITDAre was 4.7x for the quarter ended September 30, 2026
  • Recent corporate impact and sustainability achievements:
    • Named to the Top 10 in Real Estate from 3BL Media's 100 Best Corporate Citizens List
    • Named Fortune's Best Workplaces in Real Estate
    • Certified as a Great Place to Work 2026–2027
    • Named one of U.S. News & World Report’s 2026–2027 Best Companies to Work For in the Real Estate and Facilities Management category, as well as the West Region category

To learn more and view the Corporate Impact Report, please visit www.healthpeak.com/corporate-impact

THIRD QUARTER RESULTS

Three Months Ended September 30,
2026 2025
Diluted Net income (loss) per common share $ 0.02 $ (0.17 )
Diluted FFO as Adjusted per common share 0.44 0.46
Year-Over-Year Same-Store ("SS") Adjusted NOI Growth
Three Months Ended September 30,
SS Growth % % of SS
Outpatient Medical 3.1% 54.4%
Lab (0.7%) 35.6%
Senior Housing 25.9% 10.0%
Total 3.6% 100.0%

JANUS LIVING THIRD QUARTER FINANCIAL AND OPERATING HIGHLIGHTS

  • Revenue of $268 million, up 78% compared to the prior year quarter
  • Adjusted EBITDAre of $105 million, up 101% compared to the prior year quarter
  • Total Adjusted Net Operating Income of $76 million, up 81% compared to the prior year quarter
    • Same-store Adjusted NOI increased 25.9% and margin expanded 360 bps
  • Closed $1.75 billion of senior housing acquisitions during the third quarter, consisting of the previously disclosed $1.0 billion that closed from July 1 through August 3 and an additional $743 million that closed subsequent to August 3 through quarter end
  • Subsequent to quarter end and through October 30, completed approximately $370 million of senior housing acquisitions
  • As of October 30, Janus Living had approximately $1.2 billion of liquidity including cash and available credit facility capacity
  • Under binding purchase agreements for approximately $82 million of additional senior housing acquisitions

Janus Living, Inc. is a pure-play senior housing real estate investment trust that owns high-quality communities across the United States, and is majority owned by Healthpeak. Healthpeak owns 214.7 million shares of Janus Living common stock and operating partnership common units, representing a 69% equity ownership as of September 30, 2026. Janus Living is consolidated into Healthpeak’s financial statements, with the approximately 31% not owned by Healthpeak reported as noncontrolling interest.

LAB INVESTMENTS

Healthpeak has acquired, or is under contract to acquire, four life science buildings totaling approximately 510,000 square feet across three campuses for approximately $233 million. Each acquisition is part of, or an extension of, an existing Healthpeak campus where the Company's local scale and relationships position it to drive near-term leasing.

On September 30, 2026, Healthpeak acquired the senior construction loan secured by HQ Point and acquired the remaining equity interest for a combined $105 million. HQ Point is a two-building, 236,000 square foot lab campus in San Diego’s Sorrento Mesa submarket that is currently 29% occupied.

Healthpeak is also under contract to acquire two life science properties that are expected to close in the fourth quarter of 2026 or early 2027, subject to customary closing conditions.

  • South San Francisco: Healthpeak is under contract to acquire a 145,000 square foot life science building for approximately $92 million. The property is currently 49% occupied and sits adjacent to an existing 146,000 square foot Healthpeak life science building and between The Cove and The Shore, two Healthpeak campuses totaling more than 2 million square feet.
  • Cambridge: Healthpeak is under contract to acquire the remaining 51% ownership interest in 100 Acorn Park Drive, a 129,000 square foot life science building on the Cambridge Discovery Park campus for approximately $36 million. The property is currently 53% occupied. Upon closing, Healthpeak will own 100% of the 605,000 square foot Cambridge Discovery Park campus.

These three opportunistic acquisitions have a blended in-place occupancy of 41%, a current cash yield of approximately 5%, and an expected stabilized cash yield of approximately 9-10%.

A presentation highlighting these investments is available at https://ir.healthpeak.com .

OUTPATIENT MEDICAL ACQUISITION

In October 2026, Healthpeak acquired Westway One, a 146,000 square foot Class A medical training facility in Houston, Texas, for $38 million. The property is 100% leased to affiliates of HCA Healthcare, with 11 years of remaining lease term. The acquisition represents an initial capitalization rate of approximately 7.4%, adds to Healthpeak's approximately 3.4 million square foot outpatient medical portfolio in Houston, and expands its portfolio of HCA nursing and professional education facilities.

OUTPATIENT MEDICAL JOINT VENTURE RECAPITALIZATION

As previously disclosed, in July 2026, Healthpeak entered into a joint venture with affiliates of Brookfield Asset Management (“Brookfield”) through the contribution of an 86-property outpatient medical portfolio valued at approximately $2.1 billion. Healthpeak received proceeds of approximately $1.025 billion for the sale of the 49% interest.

BALANCE SHEET

Net Debt to Adjusted EBITDAre was 4.7x for the quarter ended September 30, 2026.

In October 2026, Healthpeak entered into a new $500 million unsecured delayed-draw term loan facility. The term loan matures in October 2030 and bears interest at SOFR plus 80 basis points based on Healthpeak’s current credit ratings. The unsecured term loan facility was undrawn at closing.

As of October 30, 2026, Healthpeak had $3.8 billion of liquidity, including cash, availability under its revolving credit facility, and undrawn term loan commitments.

DIVIDEND

On October 1, 2026, Healthpeak's Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of October, November, and December of 2026, representing an annualized dividend amount of $1.22 per share. The dividend is payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date. Future dividends are at the discretion of Healthpeak's Board of Directors.

Record Date Payment Date Amount
October 19, 2026 October 30, 2026 $0.10167 per common share
November 13, 2026 November 25, 2026 $0.10167 per common share
December 18, 2026 December 30, 2026 $0.10167 per common share

GUIDANCE

Healthpeak's 2026 guidance ranges are updated as follows:

Full Year 2026 As of 8/4/26 As of 11/2/26 Midpoint Change
Diluted earnings per common share $0.48 - $0.52 $0.39 - $0.41 $0.10 decrease(1)
Diluted FFO as Adjusted per share $1.73 - $1.77 $1.76 - $1.78 $0.02 increase
Total Same-Store Cash (Adjusted) NOI 0% - 1.5% 0.5% - 2.0% 50 bps increase
(1) The decrease in diluted earnings per common share guidance is primarily due to depreciation and amortization associated with senior housing acquisitions closed by Janus Living during the third quarter and through October 30, 2026. Depreciation and amortization is excluded from Nareit FFO and FFO as Adjusted, so this change has no impact on FFO as Adjusted guidance.

These estimates are based on our current view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2026. For additional guidance ranges, details, and assumptions, please see page 10 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com .

CONFERENCE CALL INFORMATION

Healthpeak has scheduled a conference call and webcast for Tuesday, November 3, 2026, at 10:00 a.m. Eastern Time.

A webcast replay will be available on Healthpeak’s website through December 3, 2026.

ABOUT HEALTHPEAK

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery.

NON-GAAP FINANCIAL MEASURES

Nareit FFO, FFO as Adjusted, Total Same-Store Cash (Adjusted) NOI, Adjusted EBITDAre, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts. See "September 30, 2026 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP, available in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results . See also the "Funds From Operations" section of this release for additional information. Additionally, as used herein with respect to Janus Living, Adjusted EBITDAre, Total Adjusted Net Operating Income, and Same-Store Adjusted NOI are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of Janus Living. See "September 30, 2026 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP, available in the Investor Relations section of the Janus Living website at https://ir.janusreit.com/financials/quarterly-results .

FORWARD-LOOKING STATEMENTS

Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release; (ii) the payment of a monthly cash dividend; and (iii) the information presented under the heading "Guidance." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. As more fully set forth under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission ("SEC"), these risks and uncertainties include, but are not limited to: changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political administration; macroeconomic trends that may increase borrowing, construction, labor and other operating costs; changes within the life science industry, and significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; operational risks associated with our senior housing properties managed by third parties, including our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”); the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses; our use of joint ventures may limit our returns on and our flexibility with jointly owned investments; our use of rent escalators or contingent rent provisions in our leases; competition for suitable healthcare properties to grow our investment portfolio; our ability to exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate and/or operate acquisitions or internalize property management; the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; environmental, social and governance and sustainability commitments and changing requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, and health and safety measures intended to reduce their spread; our past participation in the Coronavirus Aid, Relief, and Economic Security Act Provider Relief Fund and other Covid-related stimulus and relief programs; laws or regulations prohibiting eviction of our tenants; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology; the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors; volatility, disruption, or uncertainty in the financial markets; increased interest rates and borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all; an increase in our level of indebtedness; covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants; volatility in the market price and trading volume of our common stock; adverse changes in our credit ratings; the initial public offering of Janus Living may not achieve the intended benefits; our economic exposure to shifts in the price of Janus Living common stock and our ability to control the assets and activities of Janus Living; potential conflicts of interest in our relationship with Janus Living; our ability to maintain our qualification as a real estate investment trust (“REIT”); our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactions”; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels; ownership limits in our charter that restrict ownership in our stock, and provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC (“Healthpeak OP”) common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our SEC filings.

Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Healthpeak Properties, Inc.
Consolidated Balance Sheets
In thousands, except share and per share data
September 30, 2026 December 31, 2025
Assets
Real estate:
Buildings and improvements $ 18,744,157 $ 16,593,535
Development costs and construction in progress 1,026,355 1,010,657
Land and improvements 3,426,289 3,007,346
Accumulated depreciation (4,708,201 ) (4,512,443 )
Net real estate 18,488,600 16,099,095
Loans receivable, net of reserves of $8,036 and $11,345 284,203 606,020
Investments in unconsolidated joint ventures 466,114 802,601
Accounts receivable, net of allowance of $3,994 and $2,018 75,944 78,327
Cash and cash equivalents 514,310 467,457
Restricted cash 91,512 70,245
Intangible assets 917,700 654,516
Assets held for sale 48,042 80,621
Right-of-use asset 393,382 412,198
Deferred tax assets 121,663 111,248
Goodwill 68,529 68,529
Other assets 941,976 885,161
Total assets $ 22,411,975 $ 20,336,018
Liabilities and Equity
Bank line of credit and commercial paper $ 1,489,500 $ 1,078,850
Term loans 1,646,725 1,647,113
Senior unsecured notes 6,142,101 6,772,722
Mortgage debt 104,019 349,209
Intangible liabilities 146,688 173,697
Liabilities related to assets held for sale 1,035 11,900
Lease liability 288,386 296,260
Accounts payable, accrued liabilities, and other liabilities 749,010 718,509
Deferred revenue 1,039,166 985,307
Total liabilities 11,606,630 12,033,567
Commitments and contingencies
Redeemable noncontrolling interests 27,431 159,581
Common stock, $1.00 par value: 1,500,000,000 shares authorized; 689,535,670 and 695,036,731 shares issued and outstanding 689,536 695,037
Additional paid-in capital 13,470,684 12,767,914
Cumulative dividends in excess of earnings (6,322,342 ) (5,952,920 )
Accumulated other comprehensive income (loss) 28,058 (9,937 )
Total stockholders’ equity 7,865,936 7,500,094
Public investors of Janus Living, Inc. 1,270,543 —
Joint venture partners 1,283,529 295,455
Non-managing member unitholders 357,906 347,321
Total noncontrolling interests 2,911,978 642,776
Total equity 10,777,914 8,142,870
Total liabilities and equity $ 22,411,975 $ 20,336,018
Healthpeak Properties, Inc.
Consolidated Statements of Operations
In thousands, except per share data
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2026 2025 2026 2025
Revenues:
Rental and related revenues $ 545,390 $ 539,886 $ 1,617,180 $ 1,607,714
Resident fees and services 268,300 150,458 685,101 448,240
Interest income and other 7,202 15,529 43,142 47,156
Total revenues 820,892 705,873 2,345,423 2,103,110
Costs and expenses:
Operating 379,391 291,922 1,036,375 841,246
Depreciation and amortization 298,923 262,317 872,047 796,779
Interest expense 83,899 76,784 263,471 224,540
General and administrative 23,589 19,907 70,697 66,789
Transaction costs 9,738 2,420 43,059 18,169
Impairments and loan loss reserves (recoveries), net (210 ) (54 ) (3,964 ) (117 )
Total costs and expenses 795,330 653,296 2,281,685 1,947,406
Other income (expense):
Gain (loss) on sales of real estate, net — 11,500 60,657 13,136
Gain (loss) on debt extinguishments — — (403 ) —
Other income (expense), net 8,670 1,160 165,215 (9,658 )
Total other income (expense), net 8,670 12,660 225,469 3,478
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures 34,232 65,237 289,207 159,182
Income tax benefit (expense) (1,287 ) 1,206 (139 ) (3,256 )
Equity income (loss) from unconsolidated joint ventures 3,742 (176,291 ) 10,516 (176,691 )
Net income (loss) 36,687 (109,848 ) 299,584 (20,765 )
Noncontrolling interests’ share in earnings (19,424 ) (7,274 ) (35,870 ) (21,856 )
Net income (loss) attributable to Healthpeak Properties, Inc. 17,263 (117,122 ) 263,714 (42,621 )
Participating securities’ share in earnings (145 ) (134 ) (444 ) (714 )
Net income (loss) applicable to common shares $ 17,118 $ (117,256 ) $ 263,270 $ (43,335 )
Earnings per common share:
Basic $ 0.02 $ (0.17 ) $ 0.38 $ (0.06 )
Diluted $ 0.02 $ (0.17 ) $ 0.38 $ (0.06 )
Weighted average shares outstanding:
Basic 689,509 694,930 691,498 696,380
Diluted 689,509 694,930 691,781 696,380
Healthpeak Properties, Inc.
Funds From Operations
In thousands, except per share data
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2026 2025 2026 2025
Net income (loss) applicable to common shares $ 17,118 $ (117,256 ) $ 263,270 $ (43,335 )
Real estate related depreciation and amortization 298,923 262,317 872,047 796,779
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures 7,564 12,574 22,420 37,304
Noncontrolling interests’ share of real estate related depreciation and amortization (26,816 ) (3,807 ) (46,939 ) (12,686 )
Loss (gain) on sales of depreciable real estate, net — (11,500 ) (60,657 ) (13,136 )
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures — — 1,793 —
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net — — 973 —
Loss (gain) upon change of control, net(1) — — (138,343 ) —
Taxes associated with real estate dispositions — — (1,805 ) (335 )
Impairments (recoveries) of real estate, net(2) — 175,827 — 175,827
Nareit FFO applicable to common shares 296,789 318,155 912,759 940,418
Distributions on dilutive convertible units and other 4,336 4,551 13,257 13,735
Diluted Nareit FFO applicable to common shares $ 301,125 $ 322,706 $ 926,016 $ 954,153
Diluted Nareit FFO per common share $ 0.43 $ 0.45 $ 1.31 $ 1.34
Weighted average shares outstanding - Diluted Nareit FFO 703,980 709,513 705,980 711,023
Impact of adjustments to Nareit FFO:
Transaction, merger, and restructuring-related costs(3) $ 8,379 $ 2,420 $ 36,681 $ 18,169
Other impairments (recoveries) and other losses (gains), net(4) (210 ) (54 ) (3,964 ) 125
Loss (gain) on debt extinguishments — — 302 —
Casualty-related charges (recoveries), net(5) (70 ) (1,771 ) (4,451 ) 6,375
Recognition (reversal) of valuation allowance on deferred tax assets(6) — — (3,058 ) —
Total adjustments 8,099 595 25,510 24,669
FFO as Adjusted applicable to common shares 304,888 318,750 938,269 965,087
Distributions on dilutive convertible units and other 4,330 4,551 13,235 13,715
Diluted FFO as Adjusted applicable to common shares $ 309,218 $ 323,301 $ 951,504 $ 978,802
Diluted FFO as Adjusted per common share $ 0.44 $ 0.46 $ 1.35 $ 1.38
Weighted average shares outstanding - Diluted FFO as Adjusted 703,980 709,513 705,980 711,023
Other operating data:
Amortization of deferred financing costs and debt discounts (premiums) $ 8,616 $ 7,981 $ 25,879 $ 23,708
Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization 16,710 12,711 37,331 36,449
Stock-based compensation amortization expense 4,412 4,046 13,265 10,410
Deferred income taxes 930 (179 ) 4,032 4,989
AFFO capital expenditures (37,617 ) (27,261 ) (103,678 ) (76,125 )
Straight-line rents (12,876 ) (14,282 ) (35,964 ) (30,836 )
Amortization of above (below) market lease intangibles, net (6,562 ) (8,105 ) (19,466 ) (28,402 )
Other items(7) (3,909 ) (1,687 ) (9,571 ) (1,303 )
__________________________
Refer to footnotes on the next page.
(1) The nine months ended September 30, 2026 includes a gain upon change of control related to (i) the acquisition of the remaining 46.5% interest in the SWF SH JV which held 19 senior housing properties and (ii) the disposition of an 80% interest in six outpatient medical buildings to a third-party. These gains upon change of control are included in other income (expense), net in the Consolidated Statements of Operations.
(2) The three and nine months ended September 30, 2025 include other-than-temporary impairment charges on certain unconsolidated real estate joint ventures, which are recognized in equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.
(3) The three and nine months ended September 30, 2026 and 2025 include investment pursuit costs. The three and nine months ended September 30, 2026 includes transition costs associated with senior housing operators and the nine months ended September 30, 2026 includes costs related to the Janus Living IPO. The three and nine months ended September 30, 2025 include costs related to the merger with Physicians Realty Trust, which are primarily comprised of severance, legal, accounting, tax, information technology, and other costs of combining operations with Physicians Realty Trust.
(4) The three and nine months ended September 30, 2026 and 2025 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.
(5) Casualty-related charges (recoveries), net are recognized in other income (expense), net, equity income (loss) from unconsolidated joint ventures, and noncontrolling interests’ share in earnings in the Consolidated Statements of Operations.
(6) The nine months ended September 30, 2026 includes the income tax impact related to the change in tax status of certain entities in connection with the Janus Living IPO.
(7) Primarily includes: (i) amortization of deferred revenue, (ii) noncontrolling interests’ share of senior housing entrance fees in excess of (less than) the related GAAP amortization, (iii) noncontrolling interests’ share of Adjusted Funds from Operations (“AFFO”) Capital Expenditures, and (iv) our proportionate share of AFFO capital expenditures and straight-line rents from unconsolidated joint ventures.

Andrew Johns, CFA
Senior Vice President – Finance and Investor Relations
720-428-5400

Source: Healthpeak Properties, Inc.

View All News

Visit the Healthpeak | NYSE: DOC homepage

© Copyright Healthpeak Properties, Inc. 2026 - All rights reserved

opens in new window

Healthpeak Properties Declares Monthly Common

Stock Cash Dividends for the Fourth Quarter of 2026

2026-10-01

DENVER--(BUSINESS WIRE)-- Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and

developer of real estate for healthcare discovery and delivery, announced that on October 1, 2026, its Board of

Directors declared a monthly common stock cash dividend of $0.10167 per share for the fourth quarter of 2026,

payable on the payment dates set forth in the table below to stockholders of record as of the close of business on

the corresponding record date in the table below. The monthly dividend re ects an annualized dividend amount of

$1.22 per share of common stock.

Prompts

Healthpeak Properties, Inc. (ticker DOC), listed in United States.

Company History

Date Change Detail
Oct 30, 2019 Renamed HCP, INC. → HEALTHPEAK PROPERTIES, INC.
Sep 20, 2007 Renamed HEALTH CARE PROPERTY INVESTORS INC → HCP, INC.
— Different company DOC DR Holdco, LLC (CIK 1574540) is a different company that has used this ticker. Its filings are not shown here.
— Former tickers PEAK

ETFs Holding Healthpeak Properties, Inc.

ETF Weight in ETF Shares Market value As of
BKGI 6.76% 4,054,011 $ 88.499M Jul 31, 2026
SRHR 5.78% 144,063 $ 3.145M Jul 31, 2026
DIVP 3.10% 78,876 $ 1.688M Jun 30, 2026
JPRE 2.91% 708,126 $ 13.78M Nov 17, 2026
BYRE 2.69% 32,146 $ 687.924K Jun 30, 2026
DPRE 2.67% 4,872 $ 106.356K Jul 31, 2026
REIT 1.83% 49,630 $ 1.033M Aug 31, 2026
VGSR 1.41% 345,863 $ 7.401M Jun 30, 2026
FPRO 1.32% 9,954 $ 217.296K Jul 31, 2026
WTV 1.27% 1,745,731 $ 37.359M Jun 30, 2026
IYRI 1.10% 163,602 $ 3.267M Sep 30, 2026
DFAR 1.07% 4,595,901 $ 92.47M Nov 12, 2026
HIDV 0.83% 82,252 $ 1.712M Aug 31, 2026
DFGR 0.70% 1,399,153 $ 28.151M Nov 12, 2026
IALT 0.50% 2,007,360 $ 39.826M Nov 16, 2026
USAF 0.44% 3,587 $ 76.762K Jun 30, 2026
MCDS 0.36% 1,441 $ 28.042K Nov 17, 2026
CAPE 0.28% 30,759 $ 658.243K Jun 30, 2026
AVRE 0.24% 108,931 $ 2.161M Nov 16, 2026
FLDZ 0.23% 445 $ 9,523.00 Jun 30, 2026
BALI 0.21% 162,545 $ 3.225M Nov 16, 2026
SYZ 0.17% 5,334 $ 114.148K Jun 30, 2026
ENHU 0.08% 385 $ 7,638.40 Nov 16, 2026
GSPY 0.05% 17,633 $ 349.839K Nov 17, 2026
XMAG 0.03% 3,393 $ 67.922K Nov 13, 2026
AAUS 0.03% 8,620 $ 170K Nov 18, 2026
HCMT 0.02% 4,797 $ 104.719K Jul 31, 2026
CSHP 0.01% 1,245 $ 24.701K Nov 16, 2026
NPFE 0.00% 94 $ 2,052.02 Jul 31, 2026
EBI 0.00% 8 $ 166.56 Aug 31, 2026
FMDE 0.00% 54 $ 1,155.60 Jun 30, 2026
CORO 0.00% 1,299 $ 226.327K Nov 16, 2026